Bookmark

Add to MyYahoo RSS

Pharmacyclics News

News on Pharmacyclics (Ticker: PCYC) continually updated from thousands of sources around the net.

Monday Aug 18 | Benzinga

Pharmacyclics Appoints Chief Commercial Officer

Pharmacyclics, Inc. today announced that it has appointed Shawn Cline Tomasello as its Chief Commercial Officer.

Comment?

Related Topix: Startups, Oncology, Medicine, Biotech, Celgene, Healthcare Industry, Marketing

Sun Aug 17, 2014

AmericanBankingNews.com

Pharmacyclics Given Consensus Rating of "Buy" by Analysts

Pharmacyclics has earned an average recommendation of "Buy" from the nineteen analysts that are currently covering the company, American Banking & Market News reports .

Comment?

Related Topix: Startups

Thu Aug 14, 2014

Minyanville

Biotech Leads the Way

You will receive a download link right in your email inbox for each of the free reports that you choose.

Comment?

Related Topix: Startups, Biotech, Celgene, Medicine, Healthcare Industry, Gilead Sciences

Wed Aug 13, 2014

TheStreet.com

Pharmacyclics Has Edge Over Blood Cancer Competitors

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Startups, Mozilla

AmericanBankingNews.com

Pharmacyclics Receives Average Recommendation of "Buy" from Brokerages

Pharmacyclics has received an average rating of "Buy" from the nineteen ratings firms that are covering the stock, Analyst Ratings Network.com reports .

Comment?

Related Topix: Startups

Fri Aug 08, 2014

AmericanBankingNews.com

Pharmacyclics Trading Down 3.5% After Insider Selling

Pharmacyclics was down 3.5% during trading on Friday after an insider sold shares in the company, American Banking News reports.

Comment?

Related Topix: Startups

Hispanic Business

Pharmacyclics Inc - 10-Q - Management's Discussion and Analysis of...

You should read the following discussion and analysis of our financial condition and results of operations together with our interim financial statements and the related notes appearing at the beginning of this report.

Comment?

Related Topix: Startups, Lymphoma, Health, Leukemia

Tue Aug 05, 2014

AmericanBankingNews.com

Pharmacyclics Price Target Raised to $180.00 at William Blair

The firm currently has an "outperform" rating on the stock. William Blair's price objective suggests a potential upside of 51.18% from the stock's previous close.

Comment?

Related Topix: Startups

Sat Aug 02, 2014

AmericanBankingNews.com

Pharmacyclics Rating Reiterated by Zacks

's stock had its "neutral" rating reiterated by Zacks in a note issued to investors on Friday.

Comment?

Related Topix: Startups

Fri Aug 01, 2014

Forbes.com

The Best Blood Cancer Drug Launch Ever?

Last night, Pharmacyclics reported a quarterly loss of 26 cents per share, far higher than the 11 cents forecast by Wall Street analysts, as it paid $50 million to Johnson & Johnson to help cover the launch of its cancer drug Imbruvica, which J&J co-markets.

Comment?

Related Topix: Startups, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, DePuy Orthopaedics, Medical Equipment, Hospital Administration, St Peters Health Care Services

Thu Jul 31, 2014

Freshnews

Pharmacyclics Reports Second Quarter 2014 Results

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter ended June 30, 2014.

Comment?

Related Topix: Startups, Food and Drug Administration, Leukemia, Health

Tue Jul 29, 2014

SchaeffersResearch.com

Stocks On the Move: Corning Incorporated, Oshkosh Corporation, and Pharmacyclics, Inc.

U.S. stocks are marginally higher this afternoon, with solid gains for DuPont and Merck & Co., Inc. propping up the Dow.

Comment?

Related Topix: Startups, Automakers, Telecom, Corning, Electronics, Oshkosh Truck, Biotech, Merck , Medicine, Healthcare Industry, Day Trading, Personal Finance

Mon Jul 28, 2014

Freshnews

Pharmacyclics Announces Date of Conference call to discuss Financial...

Pharmacyclics, Inc. today announced that it will hold a conference call and audio webcast to discuss financial results for the second quarter of 2014 after the NASDAQ Market closes on Thursday, July 31, 2014 at 4:30 p.m. ET.

Comment?

Related Topix: Startups

SFGate

In Europe, two drugs will compete to treat rare blood cancer

In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned.

Comment?

Related Topix: Medicine, Cancer, Health, Leukemia, Biotech, Startups, Gilead Sciences, CGI Pharmaceuticals, Healthcare Industry

BioSpace

U.S. FDA Grants Regular (Full) Approval For Pharmacyclics, Inc.'s...

This is the first full FDA approval for IMBRUVICA, and was granted within six months after the accelerated approval for patients with previously treated CLL in February 2014.

Comment?

Related Topix: Healthcare Law, Food and Drug Administration, Law, Startups, Leukemia, Health

Fri Jul 25, 2014

Medical News

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA in the European Union.

Comment?

Related Topix: Startups, Marketing, Leukemia, Health, Food and Drug Administration, Medicine

Thu Jul 24, 2014

Drug Researcher

Profits and capacity utilisation up at Lonza in H1 thanks to pharma

Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.

Comment?

Related Topix: Medicine, Health, Breast Cancer, Startups

EurekAlert!

Biomedical engineer looks at new applications for novel lupus drug

Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases.

Comment?

Related Topix: Medicine, Lupus, University of Houston, Startups

Wed Jul 23, 2014

The Motley Fool

Is Gilead About to Crush Pharmacyclics Stock?

However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will regulate Imbruvica to the back-burner in chronic lymphocytic leukemia, or CLL, they should recognize that Imbruvica may do very well on its own despite the threat.

Comment?

Related Topix: Startups, Leukemia, Health, Healthcare Law, Law

Theflyonthewall.com

Pharmacyclics estimates raised ahead of Q2 report at Goldman

Pharmacyclics estimates raised ahead of Q2 report at Goldman Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data.

Comment?

Related Topix: Startups

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••